Q1 EPS Estimate for BioLife Solutions Increased by Analyst

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities researchers at HC Wainwright boosted their Q1 2025 earnings per share estimates for BioLife Solutions in a report released on Wednesday, March 5th. HC Wainwright analyst Y. Chen now anticipates that the medical equipment provider will earn ($0.02) per share for the quarter, up from their prior forecast of ($0.10). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for BioLife Solutions’ Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.16) EPS.

Several other brokerages have also recently commented on BLFS. KeyCorp raised their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Benchmark reaffirmed a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Craig Hallum raised their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Northland Securities raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. Finally, TD Cowen raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to MarketBeat, BioLife Solutions presently has a consensus rating of “Moderate Buy” and an average target price of $29.86.

BioLife Solutions Stock Up 7.1 %

BLFS opened at $26.62 on Monday. BioLife Solutions has a 1-year low of $14.84 and a 1-year high of $29.55. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -25.11 and a beta of 2.04. The business has a 50 day moving average of $26.62 and a 200-day moving average of $25.49.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. During the same period in the prior year, the business earned ($0.21) earnings per share.

Insiders Place Their Bets

In other news, CFO Troy Wichterman sold 987 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now directly owns 121,779 shares in the company, valued at approximately $3,290,468.58. This trade represents a 0.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Aby J. Mathew sold 7,604 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the sale, the executive vice president now owns 276,315 shares of the company’s stock, valued at approximately $7,551,688.95. This trade represents a 2.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,978 shares of company stock worth $322,724 over the last three months. 2.20% of the stock is currently owned by corporate insiders.

Institutional Trading of BioLife Solutions

A number of hedge funds and other institutional investors have recently made changes to their positions in BLFS. Raymond James Financial Inc. acquired a new stake in shares of BioLife Solutions in the fourth quarter valued at $20,664,000. Massachusetts Financial Services Co. MA bought a new position in BioLife Solutions in the fourth quarter valued at about $19,805,000. Point72 Asset Management L.P. bought a new position in BioLife Solutions in the fourth quarter valued at about $11,113,000. Millennium Management LLC boosted its holdings in BioLife Solutions by 49.1% in the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after acquiring an additional 377,111 shares during the last quarter. Finally, Rockefeller Capital Management L.P. boosted its holdings in BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock valued at $14,661,000 after acquiring an additional 262,504 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.